## DHR: Danaher Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.6% below STRENGTH zone (3.0-6.0%); PEG 1.99 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($222.28)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Beacon Investment Advisory Services Inc. Has $17.68 Million Stake in Danaher Corporation $DHR**
- Source: MarketBeat | 20251227T140830 | Neutral | Relevance: 100%
- Beacon Investment Advisory Services Inc. reduced its stake in Danaher Corporation by 8.4%, holding 89,179 shares valued at $17.68 million. Insider selling has also occurred, with SVP Brian W. Ellis selling 21,776 shares and other insiders selling a total of 30,248 shares in the last three months. Despite this, Wall Street analysts maintain a "Moderate Buy" consensus rating for Danaher, with a consensus target price of $248.25.

**2. Danaher (NYSE:DHR) Stock Little Changed in Life Sciences Sector**
- Source: Kalkine Media | 20251229T140821 | Neutral | Relevance: 100%
- Danaher Corporation's stock remained relatively unchanged in the life sciences sector. The company operates in life sciences, diagnostics, and environmental and applied solutions, with core offerings including analytical instruments and diagnostic systems used in various research and clinical facilities. The article discusses factual insights into Danaher's activities, manufacturing integration, digital systems, and its position within the Russell 1000 index.

**3. Danaher Corporation $DHR Position Increased by HM Payson & Co.**
- Source: MarketBeat | 20251229T123701 | Bullish | Relevance: 100%
- HM Payson & Co. significantly increased its stake in Danaher Corporation (NYSE:DHR) by 12.3% in the third quarter of 2025, now holding 168,704 shares valued at $33.45 million. This comes as Danaher reported strong Q3 earnings, beating EPS expectations and achieving a 4.4% year-over-year revenue increase. Analysts maintain a "Moderate Buy" consensus rating for DHR, with an average price target of $248.25.

**4. Norris Perne & French LLP MI Has $15.08 Million Stake in Danaher Corporation $DHR**
- Source: MarketBeat | 20251229T123001 | Bullish | Relevance: 100%
- Norris Perne & French LLP MI recently reduced its stake in Danaher Corporation (NYSE:DHR) by 12.7%, now holding 76,056 shares valued at approximately $15.08 million. Danaher, a global science and technology company, reported strong third-quarter earnings, beating analyst expectations with an EPS of $1.89 and revenue of $6.05 billion. The company has a "Moderate Buy" consensus rating from analysts with an average price target of $248.25.

**5. Ethic Inc. Lowers Position in Danaher Corporation $DHR**
- Source: MarketBeat | 20251229T102832 | Somewhat-Bullish | Relevance: 100%
- Ethic Inc. reduced its stake in Danaher Corporation by 10.2% in the third quarter, selling 6,672 shares, but still holds 58,941 shares valued at $11.69 million. Despite this reduction, institutional ownership in Danaher remains high at approximately 79%, with major acquisitions by firms like Norges Bank and Vanguard. Danaher reported strong Q3 earnings, surpassing analyst expectations with an EPS of $1.89 and revenue of $6.05 billion, and maintains a "Moderate Buy" consensus rating from analysts with an average target price of $248.25.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $240 | $230 | +4% |
| 2025-12-09 | Goldman Sachs | $265 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $270 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-02 | Morgan Stanley | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.20M) |
| Sells | 10 ($75.99M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 8.6% (+0.2%)
- Blackrock Inc.: 7.4% (+0.1%)
- JPMORGAN CHASE & CO: 5.3% (+404.7%)
- State Street Corpora: 3.9% (-0.3%)
- Capital Internationa: 2.4% (+1.9%)

### Key Risks

1. Heavy insider selling: $76M sold (10 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.99 elevated, pricing in significant growth expectations. Forward P/E 27.4x stretched relative to 9% growth. Balance sheet: $1.4B free cash flow. Insider selling cluster ($76.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $165.1B |
| Beta | 0.92 |
| 52W Range | $171.00 - $258.23 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.99 |
| Forward P/E | 27.4 |
| Current P/E | 29.9 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.7% over 5 days). Below STRENGTH zone by 2.4pp (needs >3.0% for momentum thesis). MRS_5 at 0.5% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.63% (CS: 80) | Neutral |
| RSI_14 | 58.5 | Neutral |
| MACD Histogram | 0.03 | Bullish |
| vs SMA20 | 1.015x | Above |
| vs SMA50 | 1.038x | Above |
| vs SMA200 | 1.128x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $230.68
- **Stop Loss:** $222.28 (3.6% risk)
- **Target:** $239.08 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 164
- **Position Value:** $37,831.52
- **Portfolio %:** 37.83%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-01-28 (Est: $2.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.72 | $1.89 | +9.8% |
| 2025Q2 | $1.64 | $1.80 | +9.5% |
| 2025Q1 | $1.64 | $1.88 | +14.4% |
| 2024Q4 | $2.16 | $2.14 | -1.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*